

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 13, 2008

SPHERIX® INCORPORATED

(Exact name of registrant as specified in its charter)

<u>Delaware</u>	<u>0-5576</u>	<u>52-0849320</u>
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
<u>6430 Rockledge Drive, Suite 503, Bethesda, MD</u>		<u>20817</u>
(Address of principal executive offices)		(Zip Code)
Registrant's telephone number, including area code	<u>301-897-2540</u>	

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 2 – Financial Information.

Item 2.02. Results of Operations and Financial Condition.

On November 13, 2008, the Registrant issued a press release regarding its financial results for the quarter ended September 30, 2008. A copy of the press release is attached hereto as Exhibit 99.1.

The information provided in this Current Report on Form 8-K is being provided pursuant to Item 2.02 of Form 8-K. The information in this report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in such a filing.

Section 9 – Financial Statements and Exhibits.

Item 9.01. Financial Statements and Exhibits.

Exhibit 99.1 – Press Release dated November 13, 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Spherix Incorporated
(Registrant)

By:

/s/ Claire L. Kruger
Claire L. Kruger
CEO and COO

/s/ Robert L. Clayton
Robert L. Clayton
CFO and Treasurer

Date: November 13, 2008

November 13, 2008

SPHERIX REPORTS 3RD QUARTER EARNINGS

BETHESDA, MD, Spherix Incorporated (Nasdaq:SPEX) reported a net loss for the three and nine months ended September 30, 2008 of \$1.7 million (\$0.12 per share) and \$4.8 million (\$0.34 per share), respectively. Research and development and marketing costs related to the commercialization of Naturlose as a treatment for Type 2 diabetes were approximately \$3.2 million for the nine month period ended September 30, 2008, compared to approximately \$4.5 million for the same period in 2007. Included in the prior year's income from continuing operations was a \$3.4 million tax benefit from the sale of the InfoSpherix subsidiary in August 2007. Revenue from the Health Sciences Consulting business continued its growth with a 19% increase between the second and third quarter of 2008.

“Patient recruitment for our Phase 3 clinical trial in India is off to a very encouraging start with our Contract Research Organizations reporting that 120 patients have been screened already, with a much higher enrollment rate than experienced in the U.S. portion of the trial,” said Spherix’s CFO and Treasurer, Robert Clayton.

	For the Three Months Ended Sept. 30,		For the Nine Months Ended Sept. 30,	
	2008	2007	2008	2007
Revenue from continuing operations	\$ 308,000	\$ 59,000	\$ 714,000	\$ 63,000
(Loss) income from continuing operations	\$ (1,735,000)	\$ 327,000	\$ (4,848,000)	\$ (3,655,000)
Income from discontinued operations	\$ -	\$ 4,967,000	\$ -	\$ 4,913,000
Net (loss) income	\$ (1,735,000)	\$ 5,294,000	\$ (4,848,000)	\$ 1,258,000
Net (loss) income per share				
Continuing operations	\$ (0.12)	\$ 0.02	\$ (0.34)	\$ (0.26)
Discontinued operations	\$ -	\$ 0.35	\$ -	\$ 0.35
Net (loss) income per share	\$ (0.12)	\$ 0.37	\$ (0.34)	\$ 0.09

Certain statements contained herein are “forward looking” statements as defined in the Private Securities Litigation Reform Act of 1995. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied. Factors that could cause actual results to differ materially from those expressed or implied include, but are not limited to, those discussed in filings by the Company with the Securities and Exchange Commission, including the filing on Form 8-K made on October 10, 2007.

Spherix’s mission is to create value and increase shareholder wealth through innovations that benefit our clients and the human condition. Spherix offers innovations in biotechnology, and provides technical and regulatory consulting services to biotechnology and pharmaceutical companies.

Our Internet address is www.spherix.com

#